CMR Surgical Secures $200M to Challenge U.S. Giants in Robotic Surgery
SoftBank and global investors back UK-based medtech leader as it scales Versius robot across global markets
UK-based CMR Surgical, the world’s most well-funded surgical robotics startup, has raised over $200 million in a mix of debt and equity to drive the global rollout of its Versius® surgical robot—with a particular focus on the competitive U.S. market.
The round includes continued support from existing investors SoftBank, LightRock, and Ally-Bridge, while U.S. asset manager Trinity Capital contributed $68 million in debt financing. With this latest round, CMR has now raised over $1 billion since its founding in 2014, reinforcing its position as a major challenger to American market leader Intuitive Surgical, whose market cap stands at a staggering $180 billion.
Versius, designed for colorectal, gynaecological, thoracic, urological, and general soft tissue surgeries, has already been used in over 30,000 procedures worldwide. Compact, modular, and equipped with advanced instrument control and data capture capabilities, the system is helping redefine how minimally invasive surgeries are performed globally.
“This successful funding round is a clear vote of confidence in the company, the potential of surgical robotics, and in the UK’s life science ecosystem,” said Patrick Vallance, UK Science Minister.
CEO Massimiliano Colella added, “We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets.”
CMR Surgical’s growth also reflects a wider European push in surgical robotics. Other notable players include Switzerland’s DistalMotion ($150M raised), Italy’s Medical Microinstruments ($110M), and France’s Moon Surgical ($55M).
With a $3 billion valuation and a strong trajectory, CMR Surgical is not just leading in Europe—it’s racing ahead globally in the quest to make robotic surgery the new standard of care.
